We are comparing Fortress Biotech Inc. (NASDAQ:FBIO) and Taiwan Liposome Company Ltd. (NASDAQ:TLC) on their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech Inc.	26.88M	3.26	73.01M	-0.66	0.00
Taiwan Liposome Company Ltd.	N/A	0.00	N/A	-0.51	0.00

Demonstrates Fortress Biotech Inc. and Taiwan Liposome Company Ltd. earnings per share, top-line revenue and valuation.

Profitability

Table 2 shows us Fortress Biotech Inc. and Taiwan Liposome Company Ltd.’s net margins, return on assets and return on equity.

	Net Margins	Return on Equity	Return on Assets
Fortress Biotech Inc.	-271.61%	-158.4%	-28.7%
Taiwan Liposome Company Ltd.	0.00%	0%	0%

Analyst Ratings

The table delivered features the ratings and recommendations for Fortress Biotech Inc. and Taiwan Liposome Company Ltd.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Fortress Biotech Inc.	0	0	1	3.00
Taiwan Liposome Company Ltd.	0	0	0	0.00

$11 is Fortress Biotech Inc.’s average target price while its potential upside is 669.23%.

Insider & Institutional Ownership

Institutional investors held 13.2% of Fortress Biotech Inc. shares and 2.46% of Taiwan Liposome Company Ltd. shares. 0.9% are Fortress Biotech Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Fortress Biotech Inc.	-6.85%	-1.45%	56.92%	3.55%	-50.84%	137.21%
Taiwan Liposome Company Ltd.	-0.5%	-2.14%	-6.74%	0%	0%	8.18%

For the past year Fortress Biotech Inc. has stronger performance than Taiwan Liposome Company Ltd.

Fortress Biotech, Inc., a biopharmaceutical company, engages in dermatology product sales, pharmaceutical, and biotechnology businesses in the United States. The company offers CNDO-109, a lysate that activates donor natural killer cells to treat cancer-related and other conditions; tramadol HCl, an intravenous formulation for moderate to moderately severe post-operative pain; CAEL-101 for AL amyloidosis; and CEVA101, which is in Phase II clinical study for severe traumatic brain injury in pediatric patients and adults. It also provides novel, non-chemotherapy, and immune-enhanced combination treatments for patients with solid tumor cancers; Uracil Topical Cream that is in Phase II to treat and prevent hand-foot syndrome; candidate CUTX-101, a copper histidinate injection for Menkes disease and related copper transport disorders; and novel agents for rare, neglected, or orphan disorders. In addition, the company is developing novel immunotherapies for the prevention and treatment of cancer and infectious disease; Targadox for severe acne; Luxamend, a wound cream; Ceracade, a skin emulsion; Chimeric Antigen Receptor that is in Phase I clinical trial for acute myeloid leukemia and brain cancer; and MB-101, which is in Phase I clinical trial for glioblastoma. Further, it offers full service retail brokerage and wealth management services to high net worth individual and institutional clients; investment banking, merger and acquisition, and advisory services to micro, small, and mid-cap high growth companies; trades in securities, such as making markets in micro and small-cap NASDAQ, and other exchange listed stocks; liquidity services in the United States Treasury marketplace; and tax preparation, fixed insurance sales, and licensed mortgage brokerage services. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.